The Effect of Amiloride and Spironolactone in Healthy Persons

The Effect of Amiloride and Spironolactone Measured on Cardiovascular and Kidney Related Variables in Healthy Subjects in a Double-blinded, Randomised, Placebo-controlled, Cross-over Study

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00857909

Acronym

SPAS

Enrollment

Registered

2009-03-09

Start date

2009-01-31

Completion date

2010-07-31

Last updated

2011-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

High Blood Pressure

Brief summary

This study will investigate whether retaining potassium in the body will lead to changes in blood pressure and changes in blood and urine samples.

Detailed description

The purpose is to measure the effect of amiloride and spironolactone on: 1. Renal function (GFR, u-AQP2, u-ENaCβ, u-cAMP, u-PGE2, CH20, FENa, FEK), 2. Pulsbewave velocity, augmentation index and central blood pressure, 3. Vasoactive hormones (PRC, AngII, Aldo, AVP, ANP, BNP and Endot), and 4. Ambulatory blood pressure

Interventions

DRUGAmiloride

1 tablet twice a day

DRUGSpironolactone

1 tablet twice a day

DRUGPlacebo

Placebo

DRUGPlacebo and spironolactone

5mg twice daily

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy * Non-smokers

Exclusion criteria

* Smoking * Under medical treatment

Design outcomes

Primary

Measure	Time frame
Blood pressure	2 years

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026